Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird

August 25, 2016 7:09 AM EDT
Get Alerts AMGN Hot Sheet
Price: $161.50 --0%

Rating Summary:
    17 Buy, 14 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 9 | New: 8
Trade AMGN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism, received a complete response letter. Amgen has spoken positively about the program in light of Phase 3 results. Despite the surprising decision, the analyst is not currently modeling sales for Parsabiv separate from Sensipar, and expects minimal impact to the stock.

No change to the price target of $157.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $170.84 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Related Entities

Robert W Baird

Add Your Comment